Guest guest Posted December 21, 2010 Report Posted December 21, 2010 Janssen Seeks European Marketing Authorization for Investigational Hepatitis C Treatment Telaprevir From the PharmaLive.com News Archive - Dec. 17, 2010 Janssen-Cilag International NV today announced the submission of an MAA to the EMA for telaprevir, an investigational, oral, direct-acting antiviral for the treatment of chronic genotype 1 hepatitis C virus1 (HCV. Telaprevir is a potent and selective protease inhibitor (PI), which when combined with pegylated-interferon and ribavirin (the current treatment standard), shows activity in patients that are new to treatment and who have been previously treated but were not cured, including partial responders, relapsers and those who have had little or no response (null responders) to the current standard of treatment. Quote
Guest guest Posted December 21, 2010 Report Posted December 21, 2010 Janssen Seeks European Marketing Authorization for Investigational Hepatitis C Treatment Telaprevir From the PharmaLive.com News Archive - Dec. 17, 2010 Janssen-Cilag International NV today announced the submission of an MAA to the EMA for telaprevir, an investigational, oral, direct-acting antiviral for the treatment of chronic genotype 1 hepatitis C virus1 (HCV. Telaprevir is a potent and selective protease inhibitor (PI), which when combined with pegylated-interferon and ribavirin (the current treatment standard), shows activity in patients that are new to treatment and who have been previously treated but were not cured, including partial responders, relapsers and those who have had little or no response (null responders) to the current standard of treatment. Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.